Genmab A (GMAB) Receivables - Other (2023 - 2025)

Genmab A (GMAB) has disclosed Receivables - Other for 3 consecutive years, with $62.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Receivables - Other rose 26.53% year-over-year to $62.0 million, compared with a TTM value of $62.0 million through Dec 2025, up 26.53%, and an annual FY2025 reading of $62.0 million, up 26.53% over the prior year.
  • Receivables - Other was $62.0 million for Q4 2025 at Genmab A, up from $49.0 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $62.0 million in Q4 2025 and bottomed at $43.0 million in Q4 2023.
  • Average Receivables - Other over 3 years is $51.3 million, with a median of $49.0 million recorded in 2024.
  • The sharpest move saw Receivables - Other increased 13.95% in 2024, then increased 26.53% in 2025.
  • Year by year, Receivables - Other stood at $43.0 million in 2023, then rose by 13.95% to $49.0 million in 2024, then grew by 26.53% to $62.0 million in 2025.
  • Business Quant data shows Receivables - Other for GMAB at $62.0 million in Q4 2025, $49.0 million in Q4 2024, and $43.0 million in Q4 2023.